MarketPulse

genetic medicine

4 articles
BenzingaBenzinga··Globe Newswire

MeiraGTx Acquires Johnson & Johnson's Gene Therapy for Rare Blindness

MeiraGTx acquires J&J's bota-vec gene therapy for rare blindness in $25M deal, targeting 2027 launch with promising Phase 3 clinical data.
JNJMGTXFDA approvalclinical trial
The Motley FoolThe Motley Fool··Robert Izquierdo

Beam Therapeutics CEO Sells $739K in Stock, But Strong Financials Suggest Confidence Remains

Beam Therapeutics CEO John Evans sold 30,078 shares for $739K via pre-planned tax obligation. Strong 2025 revenue growth and $1.2B cash reserves indicate company health.
BEAMbiotechinsider sale
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics' BEAM-302 Shows Promise in Alpha-1 Deficiency, Eyes Pivotal Trial

Beam Therapeutics reports positive Phase 1/2 data for BEAM-302 base editing therapy in alpha-1 antitrypsin deficiency, advancing toward pivotal development in late 2026.
BEAMclinical trialgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Calidi Biotherapeutics Advances Tumor-Targeted BiTE Platform Toward Clinical Development

Calidi Biotherapeutics advances RedTail virotherapy platform combining BiTE and IL-15 therapies for solid tumors, aiming to overcome immunosuppressive microenvironments. IND submission planned for 2026.
CLDIsolid tumorsRedTail platform